SUBSEQUENT EVENTS	12 Months Ended
Jun. 30, 2025
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS Management has evaluated all known subsequent events through the date of issuance of these consolidated financial statements and notes the following: Issuance of Common Stock For the period beginning July 1, 2025 and ending September 3, 2025, the Company issued 90,155 shares of its Class A common stock pursuant to its distribution reinvestment plan in the amount of $402,091. Repurchase Offer On June 26, 2025, under our share repurchase program, we made a tender offer to purchase up to the number of shares of our issued and outstanding Class A and Class I common stock we could repurchase with the cash we retained during the quarter ended March 31, 2025 as a result of issuing shares through our distribution reinvestment plan to those shareholders who elected to receive their distributions in the form of additional shares rather than in cash. The total cash retained during the quarter ended March 31, 2025 as a result of issuing shares through our distribution reinvestment plan prior to this tender offer was approximately $751,301. The tender offer was for cash at a price equal to the net asset value per share as of July 31, 2025. The offer expired at 4:00 P.M., Eastern Time, on July 30, 2025, and a total of 65,840 shares were validly tendered and not withdrawn pursuant to the offer as of such date. In accordance with the terms of the offer, the Company purchased all 65,840 shares validly tendered and not withdrawn at a price equal to $4.53 per share for an aggregate purchase price of approximately $298,257. Investment Activity During the period beginning July 1, 2025 and ending September 3, 2025, the Company sold 9 investments in portfolio companies totaling $14,469,469. During the period beginning July 1, 2025 and ending September 3, 2025, the Company made an investment in portfolio companies totaling $4,100,000. On August 1, 2025, Amneal Pharmaceuticals LLC fully repaid the $1,405,660 First Lien Term Loan to us at par. On August 15, 2025, Druid City Infusion, LLC repaid the $953,750 First Lien Term Loan to us at par. Senior Secured Revolving Credit Facility and OZK Credit Facility On July 8, 2025, we drew $3,400,000 on the Senior Secured Revolving Credit Facility. On July 25, 2025, August 4, 2025 and August 7, 2025, we repaid $4,700,000, 3,000,000 and 7,400,000 on the Senior Secured Revolving Credit Facility, respectively. On August 12, 2025, the Company, as servicer, entered into a $75 million senior secured revolving credit facility (the “OZK Credit Facility”) with Bank OZK, as facility agent, the Company’s wholly-owned financing subsidiary, Prospect Flexible Funding, LLC, as borrower, and the lenders party thereto. In conjunction with the closing of the OZK Credit Facility, we terminated the Senior Secured Revolving Credit Facility. On August 18, 2025 and August 20, 2025, we repaid $5,800,000 and $1,000,000 on the OZK Credit Facility, respectively. On August 27, 2025 we drew $4,000,000 on the OZK Credit Facility. As of September 3, 2025, there was no balance on the Senior Secured Revolving Credit Facility. As of September 3, 2025, there was a $40,200,000 outstanding OZK Credit Facility balance. The OZK Credit Facility is scheduled to mature on August 10, 2029 and generally bears interest at a rate of one-month SOFR + 2.50%. The OZK Credit Facility is secured by assets of the borrower. Under the Loan and Servicing Agreement, dated as of August 12, 2025, (the “Loan Agreement”), the borrower has made certain customary representations and warranties and is required to comply with various covenants, including borrowing restrictions, reporting requirements and other customary requirements for similar credit facilities. The Loan Agreement includes usual and customary events of default for credit facilities of this nature. Expense Limitation Agreement On July 25, 2025, the Company entered into a Sixth Amended and Restated Expense Limitation Agreement (the "Sixth Amended and Restated ELA") with the Adviser, which amended and restated the ELA, which was previously amended and restated on July 7, 2021, August 23, 2022, April 24, 2023 May 13, 2024, and February 12, 2025 to extend the period during which the Adviser has agreed to waive its investment advisory fees under the Investment Advisory Agreement, dated April 20, 2021, by and between the Company and the Adviser, and also requires the Adviser to reimburse the Company for certain other expenses in order to limit the Company’s operating expenses to an annual rate, expressed as a percentage of the Company’s average quarterly net assets, equal to 0.00%. The Sixth Amended and Restated ELA is in effect from July 1, 2025 until the quarter ending December 31, 2026. The Sixth Amended and Restated ELA permits for expenses waived or reimbursed by the Adviser to be recouped by the Adviser in accordance with the terms of the Sixth Amended and Restated ELA. However, pursuant to the terms of the Sixth Amended and Restated ELA, given the 0.00% annual rate, the expenses waived or reimbursed by the Adviser under the Sixth Amended and Restated ELA will effectively not be subject to recoupment. Other than these changes, the terms and conditions of the Fifth Amended and Restated ELA are identical to those of the ELA.

SUBSEQUENT EVENTS

Management has evaluated all known subsequent events through the date of issuance of these consolidated financial statements and notes the following:

Issuance of Common Stock

For the period beginning July 1, 2025 and ending September 3, 2025, the Company issued 90,155 shares of its Class A common stock pursuant to its distribution reinvestment plan in the amount of $402,091.

On June 26, 2025, under our share repurchase program, we made a tender offer to purchase up to the number of shares of our issued and outstanding Class A and Class I common stock we could repurchase with the cash we retained during the quarter ended March 31, 2025 as a result of issuing shares through our distribution reinvestment plan to those shareholders who elected to receive their distributions in the form of additional shares rather than in cash. The total cash retained during the quarter ended March 31, 2025 as a result of issuing shares through our distribution reinvestment plan prior to this tender offer was approximately $751,301. The tender offer was for cash at a price equal to the net asset value per share as of July 31, 2025. The offer expired at 4:00 P.M., Eastern Time, on July 30, 2025, and a total of 65,840 shares were validly tendered and not withdrawn pursuant to the offer as of such date. In accordance with the terms of the offer, the Company purchased all 65,840 shares validly tendered and not withdrawn at a price equal to $4.53 per share for an aggregate purchase price of approximately $298,257.

During the period beginning July 1, 2025 and ending September 3, 2025, the Company sold 9 investments in portfolio companies totaling $14,469,469.

During the period beginning July 1, 2025 and ending September 3, 2025, the Company made an investment in portfolio companies totaling $4,100,000.

On August 1, 2025, Amneal Pharmaceuticals LLC fully repaid the $1,405,660 First Lien Term Loan to us at par.

On August 15, 2025, Druid City Infusion, LLC repaid the $953,750 First Lien Term Loan to us at par.

Senior Secured Revolving Credit Facility and OZK Credit Facility

On July 8, 2025, we drew $3,400,000 on the Senior Secured Revolving Credit Facility. On July 25, 2025, August 4, 2025 and August 7, 2025, we repaid $4,700,000, 3,000,000 and 7,400,000 on the Senior Secured Revolving Credit Facility, respectively.

On August 12, 2025, the Company, as servicer, entered into a $75 million senior secured revolving credit facility (the “OZK Credit Facility”) with Bank OZK, as facility agent, the Company’s wholly-owned financing subsidiary, Prospect Flexible Funding, LLC, as borrower, and the lenders party thereto.

In conjunction with the closing of the OZK Credit Facility, we terminated the Senior Secured Revolving Credit Facility. On August 18, 2025 and August 20, 2025, we repaid $5,800,000 and $1,000,000 on the OZK Credit Facility, respectively. On August 27, 2025 we drew $4,000,000 on the OZK Credit Facility. As of September 3, 2025, there was no balance on the Senior Secured Revolving Credit Facility. As of September 3, 2025, there was a $40,200,000 outstanding OZK Credit Facility balance.

The OZK Credit Facility is scheduled to mature on August 10, 2029 and generally bears interest at a rate of one-month SOFR + 2.50%. The OZK Credit Facility is secured by assets of the borrower. Under the Loan and Servicing Agreement, dated as of August 12, 2025, (the “Loan Agreement”), the borrower has made certain customary representations and warranties and is required to comply with various covenants, including borrowing restrictions, reporting requirements and other customary requirements for similar credit facilities. The Loan Agreement includes usual and customary events of default for credit facilities of this nature.

Expense Limitation Agreement

On July 25, 2025, the Company entered into a Sixth Amended and Restated Expense Limitation Agreement (the "Sixth Amended and Restated ELA") with the Adviser, which amended and restated the ELA, which was previously amended and restated on July 7, 2021, August 23, 2022, April 24, 2023 May 13, 2024, and February 12, 2025 to extend the period during which the Adviser has agreed to waive its investment advisory fees under the Investment Advisory Agreement, dated April 20, 2021, by and between the Company and the Adviser, and also requires the Adviser to reimburse the Company for certain other expenses in order to limit the Company’s operating expenses to an annual rate, expressed as a percentage of the Company’s average quarterly net assets, equal to 0.00%. The Sixth Amended and Restated ELA is in effect from July 1, 2025 until the quarter ending December 31, 2026. The Sixth Amended and Restated ELA permits for expenses waived or reimbursed by the Adviser to be recouped by the Adviser in accordance with the terms of the Sixth Amended and Restated ELA. However, pursuant to the terms of the Sixth Amended and Restated ELA, given the 0.00% annual rate, the expenses waived or reimbursed by the Adviser under the Sixth Amended and Restated ELA will effectively not be subject to recoupment. Other than these changes, the terms and conditions of the Fifth Amended and Restated ELA are identical to those of the ELA.